Lupus & antiphospholipid syndrome
Renal interferon-inducible protein 16 expression is associated with disease activity and prognosis in lupus nephritis
Authors' conclusion
Renal IFI16 expression is a potential biomarker for disease activity and clinical prognosis in LN patients.
Study context
- Population
- Patients with lupus nephritis (LN), diabetic kidney disease (DKD), minimal change disease (MCD), IgA nephropathy (IgAN) and normal controls
- Participants
- 104 / 12 / 12 / 12 / 14
- Comparison
- Renal IFI16 expression in LN vs DKD, MCD, IgAN and normal controls
- LNn = 104
- DKDn = 12
- MCDn = 12
- IgANn = 12
- Normal controls (NC)n = 14reference
- Outcome
- Renal IFI16 expression
Methodological detailsbioinformatics and machine learning, immunohistochemistry and multiplex immunofluorescence
- Bioinformatics and machine learning
- Immunohistochemistry and multiplex immunofluorescence
Main finding
As reported in the abstract
- IFI16 highly expressed in kidneys of LN patients vs MCD, DKD, IgAN or NC
- Glomerular IFI16 correlated with pathological activity indices; tubulointerstitial IFI16 with chronicity indices
- Renal IFI16 positively associated with systemic lupus erythematosus disease activity index (SLEDAI) and serum creatinine, negatively with baseline eGFR and serum C3
- Higher IFI16 expression closely related to poorer prognosis of LN patients
Original publication
Renal interferon-inducible protein 16 expression is associated with disease activity and prognosis in lupus nephritis. Arthritis Res Ther. Published 1 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →